PP-23

Start of salvage treatment for persistent positive biopsies after HIFU

R. Sanchez-Salas[1], D. Prapotnich[1], F. Secin[2], **E. Barret**[1], F. Rozet[1], M. Galiano[1], A. Mombet[1], N. Cathala[1], X. Cathelineau[1]

[1] *Institut Montsouris, Paris, France*

[2] *CEMIC, Buenos Aires, Argentina*

Introduction & Objectives: To report long term oncologic outcome of HIFU-Ablatherm in patients with low risk localized prostate cancer treated with HIFU and receiving secondary therapy due to positive persistent biopsies.

Material & Methods: From December 1995 to April 2010, 534 patients with localized PCA were treated in our institution. Patients with available positive biopsies and long term follow-up were considered for the study. Data on Prostate-specific antigen (PSA), clinical stage, cancer control, recurrence, post-HIFU biopsies and secondary treatment patterns have been prospectively collected and retrospectively analyzed. Sextant biopsies were indicated at rising PSA under physicians criteria. Chi-square test was used for statistical analysis distribution with a p=<0.05. Salvage free survival (SFS) was estimated with Kaplan-Meier curves.

Results: We identified 56 patients with more than 5 years of reliable follow-up data and post HIFU positive biopsies. Median post-biopsy follow-up was 2 years (0.6 , 10.2). Median age at time of treatment was 73 years (range 57-82), median PSA 8.04 ng/ml (range 2.48-28), median prostate volume 30 g (15-65) and median Gleason score 6 (4-7). Stratification according to D'Amico's risk group was low, intermediate, and high in 29 (52%), 21 (37%) and 6 (11%) of patients, respectively. The median PSA nadir was 1.4 ng/ml (0.1-13.94) with a median time to nadir of 9.8 weeks (4-49). Phoenix biochemical recurrence and salvage treatment had a related distribution in patients with positive biopsies (Contingency table). Secondary therapy free survival rates were 75%, 65%, and 100% (N.S.) for low-, intermediate-, and high-risk patients, respectively. Secondary treatment was 23(41%), 16(29%), 1(2% for hormonotherapy, radiotherapy and brachytherapy, respectively] 43 (17%) patients received re -treatment with HIFU. 16 (21.4%) of the patients were re-treated with HIFU, and 23 (41%), 15 (27%) and 1 (2%) received salvage hormonotherapy, radiotherapy and brachytherapy, respectively.

Conclusions: Post-HIFU biopsies have a significant impact in therapeutic decision for patients with localized prostate cancer. The procedure should be incorporated in a standardized way during post-HIFU follow-up.

	Phoenix	
Salvage treatment	+	-
+	36 (90%)	4 (10%)
-	10 (62%)	6 (38%)

Contingency table